Background: In high-resource settings, the HIV-attributable risk of myocardial infarction (MI) is higher among women than among men. The extent to which unique mechanisms contribute to MI risk among women vs. men with HIV remains unclear.
INTRODUCTION
Studies conducted in high-resource settings suggest that the HIV-attributable risk of myocardial infarction (MI) is higher among women than among men. [1] [2] [3] [4] In this study, we endeavored to assess whether the mechanisms predisposing to MI among individuals with HIV differ by sex. To do so, we performed new analyses focused on ART-treated HIVinfected individuals without known cardiovascular disease (CVD) who had been previously recruited to undergo coronary computed tomography angiography (CTA). [5] [6] [7] Previous studies from our group provide critical context for the current investigation. Initial studies focused on men revealed that asymptomatic HIV-infected men (vs. men without HIV) had a significantly increased prevalence of subclinical coronary atherosclerotic plaque 5 and an increased prevalence and burden of coronary plaque with high-risk morphology. 8 High-risk morphology plaque-that is, plaque with features of low-attenuation or positive remodeling 9 -is prone to rupture, resulting in MI. 10 Next, studies led by Fitch et al illustrated that asymptomatic HIV-infected women (vs. women without HIV) had an increased proportion of noncalcified plaque, and that those HIV-infected women with noncalcified plaque had the highest levels of systemic immune activation. 7 In a secondary four-group comparison of women and men with and without HIV, Fitch et al 7 also showed a significant difference in overall plaque prevalence across groups, with plaque prevalence highest among HIVinfected men.
In this study, we built on the aforementioned findings. For the first time, we systematically compared plaque characteristics-including high-risk morphology plaque-among HIV-infected women and men, controlling for differences between groups. For this purpose, we generated novel data on subclinical high-risk morphology plaque characteristics among asymptomatic HIV-infected women. To maximize the generalizability and clinical relevance of our findings on sex differences in subclinical coronary atherosclerotic plaque, we focused our analyses on those HIV-infected women and men who reported stable use of ART. Strong imperatives exist to examine whether mechanisms fueling MI risk among ARTtreated HIV-infected individuals may differ by sex. Indeed, without rigorous sex differences research, mechanistic insights from studies enrolling all-male or predominantly-male cohorts may be misapplied to women.
METHODS

Study Design and Participants
In this study, data on subclinical coronary atherosclerotic plaque-including high-risk morphology plaque-were compared among previously recruited HIV-infected women and men without known CVD. These participants (ages 18-60 years) had been previously recruited from the greater Boston area to undergo coronary CTA and detailed metabolic/immune phenotyping. [5] [6] [7] Recruitment took place between September 2006 and October 2012. Data on general and high-risk coronary plaque characteristics had been previously assessed among HIV-infected men 5, 6, 8 and data on general coronary plaque characteristics had been previously assessed among HIV-infected women. 7 Data on high-risk coronary plaque characteristics among HIV-infected women were newly generated for the purpose of these analyses. Consonant with the current HIV standard of care, the analyses we present were restricted to those HIV-infected women and men on stable ART (.3 months) who had successfully completed coronary CTA procedures. All participants provided informed consent. Approval for the study was obtained from the Institutional Review Boards of the Massachusetts General Hospital and the Massachusetts Institute of Technology.
Study Procedures Immune and Metabolic Phenotyping
Participants underwent history and physical examination. Select HIV-specific parameters-including time since HIV diagnosis, ART regimen, total duration of ART, and nadir CD4 + T-cell count-were participant-reported. Fasting total cholesterol, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), triglycerides, and hemoglobin A1c were quantified using standard techniques. Flow cytometry was performed to assess CD4 + T-cell counts, and HIV viral load was quantified with ultrasensitive reverse-transcription polymerase chain reaction (Roche COBAS Amplicor). ELISAs were used to assess levels of soluble CD14 (sCD14) (R&D Systems) and soluble CD163 (sCD163) (Trillium). Abdominal visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT) areas were determined using single slice computed tomography at the level of the fourth lumbar vertebra.
Coronary CTA and Coronary Atherosclerotic Plaque Analysis
Coronary CTA was performed using a 64-slice CT scanner or 64-slice dual-source CT scanner (Siemens Medical Solutions), as previously detailed. [5] [6] [7] [8] Experienced cardiovascular imagers blinded to participants' clinical status assessed plaque parameters including any plaque, plaque type (calcified, noncalcified), plaque with high-risk morphology features (positive remodeling, low-attenuation), and obstructive plaque ($70% stenosis). With respect to plaque morphology, high-risk plaque features were defined as follows: lowattenuation plaque had a mean minimum attenuation ,40 Hounsfield Units; positively remodeled plaque had a [plaque segment diameter/reference segment diameter] .1.05 indicating eccentric volume gain. 8 Examples of select plaque characteristics are depicted in Figure 1 . Plaque data on women vs. men were read by a limited number of experienced imagers, who had received similar training and used the same diagnostic criteria.
Statistical Analysis
The outcomes of interest in our analysis were differences in prevalence and burden of any plaque and of high-risk morphology plaque between HIV-infected women and men. Normality of variables was determined using the Shapiro-Wilk test and confirmed by visual assessment. Normally distributed variables are shown as mean 6 SD, and nonnormally distributed variables are shown as median [interquartile range]. For data on plaque segments, both mean 6 SD and median [interquartile range] are presented descriptively. Demographic, immunologic, and metabolic parameters were compared between HIV-infected women and men. Plaque characteristics were then compared between HIVinfected women and men in the sample overall, as well as in the subset of participants with any plaque. For these analyses, student two-tailed t test was used for normally distributed continuous variables, Wilcoxon rank-sum test was used for nonnormally distributed continuous variables, and x 2 test was used for categorical variables. Multivariable logistic regression models were constructed to identify independent relationships of sex with presence of any plaque and presence of high-risk morphology plaque while adjusting for relevant traditional and HIV-specific CVD risk factors that differed between women and men. Adjusted odds ratios are reported with 95% confidence intervals. Statistical significance was defined as P # 0.05. Statistical analyses were performed using JMP Pro software (version 12.0, SAS Institute, Cary, NC).
RESULTS
Participant Characteristics
The participants studied consisted of 48 ART-treated HIV-infected women and 97 ART-treated HIV-infected men. Fifty percent of women were postmenopausal as defined by no menses for at least 1 year. Six percent of women were taking hormonal contraceptives. Demographic and clinical characteristics of study participants are compared in Table 1 (84% vs. 85%, P = 0.83). Women and men had comparable nucleoside reverse transcriptase inhibitor and protease inhibitor use, whereas nonnucleoside reverse transcriptase inhibitor use was lower in women compared with men (17% vs. 49%, P , 0.0001).
With respect to traditional CVD risk factors, ARTtreated HIV-infected women and men had similar body mass index (BMI) (27.5 6 5.2 vs. 26.2 6 4.6 kg/m 2 , P = 0.17), smoking status (50% vs. 40%, P = 0.24), and history of intravenous drug use (25% vs. 20%, P = 0.46 
Coronary Plaque Characteristics Among Participants Overall
Coronary plaque prevalence and characteristics among HIV-infected women and men are shown in Table 2A . In new analyses among ART-treated participants, we show that HIVinfected women had a lower prevalence of any subclinical coronary atherosclerotic plaque compared with HIV-infected men (35% vs. 62%, P = 0.003) (Fig. 2) . Women also had a lower number of vascular segments with plaque (P = 0.01) and a lower prevalence of obstructive plaque ($70% stenosis) (0% vs. 5%, P = 0.05). Despite the lower prevalence and burden of any coronary plaque among women, there was no significant difference in the prevalence of noncalcified plaque or number of noncalcified plaque segments between groups. In terms of high-risk morphology plaque features, women had a lower prevalence of positively remodeled plaque (25% vs. 51%, P = 0.003) (Fig. 2) and a lower number of positively remodeled plaque segments (P = 0.002) compared with men. There was no significant difference in the prevalence of lowattenuation plaque or the number of low-attenuation plaque segments between groups.
Multivariable Analyses of Presence of Plaque and Presence of Positively Remodeled Plaque Among Participants Overall
We next sought to investigate whether the lower prevalence of any plaque or of positively remodeled plaque among ART-treated HIV-infected women compared with men would persist when controlling for pertinent traditional and HIV-specific CVD risk factors that differed between groups (Table 3) . We found that male sex was associated with The relationships of sex with any plaque and positively remodeled plaque were consistent in a model that adjusted for ART regimen (eg, nonnucleoside reverse transcriptase inhibitor based, protease inhibitor based, and other) rather than each ART class individually (see Table 1 , Supplemental Digital Content, http://links.lww.com/QAI/B143).
Coronary Plaque Characteristics Among Participants With Plaque
From the overall ART-treated HIV-infected sample, 17 women (35%) and 60 men (62%) had plaque on coronary CTA. Among this subset of participants, sex-specific comparisons of coronary plaque burden and plaque characteristics are shown in Table 2B . The number of vascular segments with plaque was comparable between groups. Although the prevalence of obstructive plaque ($70% stenosis) tended to be lower in women compared with men, this difference was not significant (0% vs. 8%, P = 0.10). By contrast, ARTtreated HIV-infected women with plaque had an increased number of noncalcified plaque segments (P = 0.02). These women also had an increased proportion of noncalcified plaque (75 6 28% vs. 53 6 38%, P = 0.03), consistent with previous reports. 7 As for high-risk morphology plaque features, there was no sex difference in the prevalence of positively remodeled plaque (71% vs. 82%, P = 0.33). However, women had a lower proportion of plaque segments with positive remodeling (33 6 33% vs. 62 6 37%, P = 0.004) and tended to have a lower number of positively remodeled segments (P = 0.09). The prevalence and extent of low-attenuation plaque were comparable between groups.
DISCUSSION
Our study revealed significant sex differences in coronary atherosclerotic plaque among asymptomatic HIVinfected individuals on ART. Male sex conferred nearly 4-fold increased odds of having any subclinical coronary atherosclerotic plaque and high-risk morphology subclinical coronary atherosclerotic plaque characterized by positive remodeling. These findings held even after controlling for traditional and HIV-specific CVD risk factors that differed between groups. Moreover, compared with asymptomatic HIV-infected men, HIV-infected women had a lower prevalence of obstructive coronary artery disease and a lower number of vascular segments affected by plaque despite having lower rates of statin use. Given that epidemiologic studies have shown an increased HIV-attributable risk of MI among women vs. men, 1-4 our findings imply that mechanisms other than gradual epicardial vessel occlusion and/or sudden macroscopic plaque rupture may contribute to MI among women with HIV. Among our sample of asymptomatic ART-treated HIVinfected individuals, women (vs. men) had a lower prevalence of coronary atherosclerotic plaque, a lower prevalence of obstructive plaque, and a reduced plaque burden (number of coronary segments with plaque). Sex differences in coronary plaque prevalence remained significant even after controlling for CVD risk factors that differed between groups with male sex conferring markedly increased odds of plaque. These findings are consonant with data from several general population studies exploring sex differences in coronary atherosclerotic plaque. For example, in a large study of asymptomatic individuals undergoing coronary CTA, male sex was strongly associated with prevalence of any plaque in adjusted models [OR 5.21, 95% CI: (3.20, 8.49)]. 11 Furthermore, several large studies of individuals undergoing coronary CTA to evaluate stable angina suggested that symptomatic women had a lower prevalence of any plaque 12, 13 and/or obstructive plaque 12-14 compared with symptomatic men. The number of segments with calcified and/or mixed coronary atherosclerotic plaque also was shown to be lower in symptomatic women compared with men. 14 Our finding that HIV-infected women had a lower prevalence of obstructive plaque and reduced plaque burden compared with men is potentially clinically relevant, as plaque burden/extent of disease has been shown in general population studies to portend adverse cardiovascular events. 15 Our investigation introduces the first assessment of high-risk morphology plaque features among asymptomatic HIV-infected women. We found that asymptomatic ARTtreated HIV-infected women had a lower prevalence of positively remodeled plaque than asymptomatic HIVinfected men, even after controlling for relevant CVD risk factors. Positively remodeled plaque represents plaque that prompts the affected arterial segment to balloon outward, eccentrically. 16 Such plaque is identified by coronary CTA when the affected segment diameter is noted to exceed the reference segment diameter. 9 Pathologic studies have shown that coronary atherosclerotic plaques with a large, necrotic lipid core tend to cause positive remodeling, whereas fibrous plaques do not. 17 Positive remodeling is widely believed to characterize coronary atherosclerotic plaques that provoke ischemia 18 and unstable angina, 19 and that are prone to rupture, resulting in acute coronary syndrome. 10, 20 Our finding that asymptomatic ART-treated HIV-infected women had a lower prevalence of positively remodeled plaque compared with asymptomatic HIV-infected men is novel and clinically relevant. This finding also extends FIGURE 2. Prevalence of any plaque and any positively remodeled plaque among ART-treated HIV-infected women and men. HIV-infected women had a lower prevalence of any coronary plaque (35% vs. 62%, P = 0.003) and of positively remodeled plaque (25% vs. 51%, P = 0.003) compared with HIV-infected men. P values were determined using x 2 test. NNRTIs, nonnucleoside reverse transcriptase inhibitors; NRTIs, nucleoside reverse transcriptase inhibitors; PIs, protease inhibitors. previous work demonstrating that asymptomatic HIVinfected men had an increased prevalence and burden of positively remodeled plaque compared with non-HIV-infected men. 8, 21 Of interest, although general population studies have not previously reported on sex differences in positively remodeled plaque prevalence among asymptomatic individuals, an intravascular ultrasound study performed on symptomatic individuals undergoing cardiac catheterization did suggest sex differences. In particular, women in this previous study were noted to have a significantly lower remodeling index than men. 22 The reduced prevalence of coronary plaque and positively remodeled plaque among asymptomatic ART-treated HIV-infected women suggests that mechanisms other than gradual luminal occlusion and/or plaque rupture may contribute to ischemic heart disease among this group. General population literature on sex differences in coronary atherosclerotic plaque provides key context in this regard. Women (vs. men) who survived an MI were less likely to exhibit obstructive plaque on coronary angiography 23 or culprit plaque rupture on coronary intravascular ultrasound. 24 Analogously, women (vs. men) who experienced sudden cardiac death were less likely to exhibit rupture of a thin-capped fibroatheroma (thin fibrous cap/large necrotic core) on coronary artery pathologic analyses at autopsy. 25 Among these women, erosion of a more fibrotic plaque type rich in smooth muscle cells and proteoglycans was more commonly observed in coronary artery sections. 25 Thus, among HIVinfected women, one pathway to MI may be repeated erosion of (initially) nonobstructive plaque.
A second potential pathway to ischemia among women -and particularly, women with HIV-may be microvascular disease. A highly informative general population study by Taqueti et al has provided support for this concept. In this study, excess CVD risk among women was attributable, not to obstructive epicardial artery disease, but rather to reduced coronary flow reserve-an integrated measure of functionally significant pathology in large and small vessels. 26 Among HIV-infected women, heightened systemic immune activation/inflammation 7 may be expected to contribute uniquely to endothelial dysfunction/microvascular disease and downstream comorbidities. 27, 28 Our finding that HIV-infected women had a lower prevalence of high-risk, rupture prone plaque than HIVinfected men also dovetails with recent findings by Crane et al 29 29 showed that HIVinfected women had a predilection toward type II MI (resulting from mismatch of oxygen supply and demand), whereas HIV-infected men had a predilection toward type I MI (resulting from instability of coronary atherosclerotic plaques). Taken together, these data suggest that MI mechanisms differ among HIV-infected women and men and reinforce the need to tailor diagnostic/therapeutic strategies to the dominant sex-specific pathophysiologic processes at play.
Of note, among those asymptomatic ART-treated HIVinfected women in our sample who did demonstrate subclinical coronary atherosclerosis, plaque burden was not low and plaque characteristics were not benign. HIV-infected women (vs. men) had a similar number of vascular segments with plaque, prevalence and extent of low-attenuation plaque, and prevalence of positively remodeled plaque-although the extent of positively remodeled plaque remained higher in men. Moreover, those ART-treated HIV-infected women with subclinical coronary atherosclerotic plaque had an increased number of noncalcified plaque segments. This subgroup also had an increased proportion of noncalcified plaque, consistent with previous findings by Fitch et al 7 in a mixed group of ART-treated and ART-untreated women. General population studies have revealed that symptomatic women had a greater percentage of noncalcified plaque than symptomatic men. 14 Moreover, among symptomatic individuals with any plaque, noncalcified plaque correlated more closely with major adverse cardiovascular events than did calcified plaque. 15 Thus, although an absence of macroscopic plaque among asymptomatic HIV-infected women may not necessarily be reassuring, the presence of plaque in this group could be particularly worrisome.
Study limitations include a relatively small sample of HIV-infected individuals recruited from one geographic area, precluding our ability to disentangle whether differences in use of specific antiretroviral agents influenced differences in atherogenesis. Of note, however, our analysis represents one of the largest and most comprehensive coronary CTA-based assessments of plaque morphology among HIV-infected women on ART. Although the women and men in this study were not matched explicitly, the groups were comparable with respect to age, key traditional CVD risk factors (eg, BMI, smoking status, and LDL-C), and important HIVspecific CVD risk factors (eg, time since HIV diagnosis, total duration of ART, CD4 + T-cell count, and viral load). Moreover, the lower prevalence of any plaque and of positively remodeled plaque among women vs. men remained significant even after adjusting for relevant parameters that differed between sexes. Select HIV-specific CVD risk factors (eg, time since HIV diagnosis, total duration of ART, and nadir CD4 + T-cell count) were participant-reported and could not be specifically verified. Plaque data on women vs. men were read by a limited number of cardiovascular imagers-all blinded to participant status-who received similar training and used the same diagnostic criteria. Finally, our sample was limited to HIV-infected women and men without clinical CVD, and thus, by design, we lack information about coronary plaque characteristics among HIV-infected individuals with anginal symptoms. However, our findings on sex differences in coronary plaque in an asymptomatic group of HIV-infected participants were consonant with those from large-scale general population studies enrolling symptomatic patients without HIV.
Overall, we found that HIV-infected women on ART had a lower prevalence of subclinical coronary atherosclerotic plaque and positively remodeled plaque as well as a lower burden of overall plaque and positively remodeled plaque, compared with HIV-infected men on ART. However, those HIV-infected women who did have coronary atherosclerotic plaque had a reduced extent of positively remodeled plaque but an increased extent of noncalcified plaque (vs. men). Additional research is needed to explain why the HIVattributable risk of MI is higher among women vs. men [1] [2] [3] [4] despite a lower prevalence of macroscopic subclinical atherosclerosis among women. The REPRIEVE trial (Randomized Trial to Prevent Vascular Events in HIV) and embedded mechanistic CTA substudy will provide critical data in this regard. Only by understanding distinct mechanisms of HIV-associated CVD at play in women can we deliver "precision" preventive care to this population of 17 million worldwide. 30 
